Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zymeworks (ZYME) Cash & Current Investments (2021 - 2025)

Zymeworks' Cash & Current Investments history spans 3 years, with the latest figure at $295.4 million for Q3 2023.

  • For Q3 2023, Cash & Current Investments rose 77.7% year-over-year to $295.4 million; the TTM value through Sep 2023 reached $295.4 million, up 77.7%, while the annual FY2022 figure was $492.2 million, 94.86% up from the prior year.
  • Cash & Current Investments for Q3 2023 was $295.4 million at Zymeworks, down from $340.1 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $492.2 million in Q4 2022 and bottomed at $166.2 million in Q3 2022.
  • The 3-year median for Cash & Current Investments is $317.7 million (2023), against an average of $314.6 million.
  • The largest annual shift saw Cash & Current Investments surged 94.86% in 2022 before it surged 77.7% in 2023.
  • A 3-year view of Cash & Current Investments shows it stood at $252.6 million in 2021, then soared by 94.86% to $492.2 million in 2022, then tumbled by 39.99% to $295.4 million in 2023.
  • Per Business Quant, the three most recent readings for ZYME's Cash & Current Investments are $295.4 million (Q3 2023), $340.1 million (Q2 2023), and $340.8 million (Q1 2023).